Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis

美波利祖马布 医学 奥马佐单抗 苯拉唑马布 嗜酸性粒细胞增多 哮喘 杜皮鲁玛 肉芽肿伴多发性血管炎 嗜酸性 不利影响 内科学 嗜酸性粒细胞增多症 皮肤病科 免疫学 血管炎 嗜酸性粒细胞 病理 免疫球蛋白E 抗体 疾病
作者
Federica Davanzo,Maria Rita Marchi,Luca Iorio,Michela Bortoli,Andrea Doria,Roberto Padoan
出处
期刊:Autoimmunity Reviews [Elsevier BV]
卷期号:23 (3): 103503-103503 被引量:17
标识
DOI:10.1016/j.autrev.2023.103503
摘要

Monoclonal antibodies targeting type 2 inflammation are promising treatments for eosinophilic-associated diseases. There is growing interest in the potential benefits of combining two biologics to treat patients with poorly controlled conditions. We present a case of a 54-year-old female patient affected with a relapsing-refractory ANCA myeloperoxidase positive eosinophilic granulomatosis with polyangiitis (EGPA), presenting with difficult-to-treat asthma and rhino-sinusitis manifestations. She failed several biologics, including omalizumab 300 mg, mepolizumab 100 mg, and benralizumab 30 mg every 8 weeks. A switch to dupilumab led to significant eosinophilia (7.69 × 109/L) as well as systemic symptoms, and a deterioration of asthma control. Therefore, a combination of dupilumab-benralizumab was started, leading to better nasal and ear outcomes, asthma control and decrease in blood eosinophils. During the 12-month treatment, no adverse effects were observed. We conducted an extensive literature search in MEDLINE for original articles published until August 1st, 2023 reporting the combination of anti-type 2 biologics. A total of 51 cases were retrieved from the literature. Omalizumab was the most frequently combined drugs (34 cases). Combination therapy led to reduction of asthma exacerbations and glucocorticoid intake, though was ineffective only for one EGPA patient. Only one patient on omalizumab-mepolizumab therapy reported a mild adverse reaction. Combination biologic therapies for conditions which share pathogenic pathways appears to be both safe and effective. This approach may benefit patients with uncontrolled conditions and counter side effects of biologics, like dupilumab-related hypereosinophilia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
04d的应助被科研通管家采纳,获得10
刚刚
天天快乐的应助被科研通管家采纳,获得10
刚刚
歪比巴卜完成签到 ,获得积分10
刚刚
打打的应助被科研通管家采纳,获得10
刚刚
刚刚
科目三的应助被科研通管家采纳,获得10
刚刚
Akim的应助被科研通管家采纳,获得10
刚刚
www发布了新的文献求助10
1秒前
1秒前
李健的应助被科研通管家采纳,获得10
1秒前
rain关注了科研通微信公众号
1秒前
汉堡包的应助被科研通管家采纳,获得10
1秒前
天天快乐的应助被科研通管家采纳,获得10
1秒前
汉堡包的应助被科研通管家采纳,获得10
1秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
1秒前
顾矜的应助被科研通管家采纳,获得10
1秒前
goodc完成签到,获得积分10
1秒前
情怀的应助被科研通管家采纳,获得10
1秒前
李爱国的应助被科研通管家采纳,获得10
2秒前
小海萍完成签到,获得积分20
2秒前
2秒前
2秒前
2秒前
怡然的晓丝完成签到 ,获得积分10
2秒前
孙浩文发布了新的文献求助10
2秒前
stella完成签到 ,获得积分10
3秒前
5秒前
小梨呀完成签到,获得积分10
6秒前
所所的应助被糯洛采纳,获得30
6秒前
6秒前
6秒前
柯迎南发布了新的文献求助10
7秒前
Atom关注了科研通微信公众号
7秒前
8秒前
yiyi完成签到,获得积分10
8秒前
dayandnight7完成签到,获得积分10
8秒前
辅助但上分完成签到,获得积分20
9秒前
研友_VZG7GZ的应助被Sh采纳,获得10
9秒前
科研通AI6.4的应助被小浪矢采纳,获得10
10秒前
zj发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192209
求助须知:如何正确求助?哪些是违规求助? 9578801
关于积分的说明 21861940
捐赠科研通 7791695
什么是DOI,文献DOI怎么找? 3436846
关于科研通互助平台的介绍 2560562
邀请新用户注册赠送积分活动 2483617